Don Sapatkin
State Medicaid programs in the Philadelphia region denied nearly half the coverage requests for the most effective - and expensive - treatments for chronic hepatitis C, according to a University of Pennsylvania study that will be presented on Monday.
The findings, based on prescription data for Pennsylvania, New Jersey, Delaware and Maryland, appear to confirm widespread concerns that state budgets are effectively limiting treatment for a potentially fatal condition.
The findings, based on prescription data for Pennsylvania, New Jersey, Delaware and Maryland, appear to confirm widespread concerns that state budgets are effectively limiting treatment for a potentially fatal condition.
No comments:
Post a Comment